Navigation Links
Lotus Pharmaceuticals Announces Second Quarter 2008 Results
Date:8/18/2008

the project is an estimated RMB 50 million (approximately $7.1 million).

2008 Outlook

"We recently obtained the patent and exclusive production rights to a new asthma drug, Laevo-Bambutero, which we plan to launch in 2012 after we receive approval from the SFDA. We currently have fourteen drugs for which we are seeking SFDA approval, and plans for manufacturing a number of new pharmaceutical products," said Dr. Liu. "In 2008, we expect strong revenue growth to be led by our distribution of pharmaceutical products manufactured by third-parties and our best selling branded products. For the full year 2008, because of our growing distribution network, we remain confident that we will meet our 'make good' net income target of $13.1 million."

"As part of our longer term growth strategy, we began the process of acquiring land use rights on which to construct a product development and manufacturing facility that will allow us produce a wide range of new pharmaceutical products. We hope to have the facility completed by the end of 2010. However, we may adjust the time line depending on our availability of working capital and external funds. We obtained the land use rights at a favorable price and may be able to monetize a portion of them in the future."

Conference Call

Lotus' management will host a conference call at 10:00 a.m. Eastern Time on Monday, August 18, 2008 to discuss results for the quarter ended June 30, 2008. To participate in this live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: 888- 481-7939. International callers should call 617-847-8707. The Conference Pass Code is 306 650 22.

Replay of the conference call will be available from 12 p.m. Eastern Time on Monday, August 18 for fourteen days. To access the replay, call 888-286- 8010. International callers should call 617-801-6888. The Conference Pass Code is 939 152 01.

Use of Non-GAAP Financi
'/>"/>

SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 1000 balances – 4 steps – One ... needs and expertly narrows down the mass of product ... even terminals. , First, select the working environment, ... readability instead) and define the accuracy – it’s really ... down the list to models that fit best with ...
(Date:7/24/2014)... Draper University, a top program ... announce that for 6 weeks this summer, 39 ... on the Draper University campus in the heart ... focused on entrepreneurship, building real-world skills, and “learning ... its sixth cohort, continues to refresh its curriculum ...
(Date:7/24/2014)... July 24, 2014   Cypher Genomics, Inc., ... appointment of Adam Simpson as president ... rapid and comprehensive annotation and interpretation of individual ... "Cypher,s technology has the potential to ... enhancing diagnostic accuracy, optimizing therapeutic approaches and reducing ...
(Date:7/24/2014)... July 24, 2014 The patent ... molecular diagnostic test results. It also enables true ... the validation and reporting of high profile assays ... is a rapidly growing area of biotechnology that ... predisposition, cancer, and companion diagnostics in personalized medicine. ...
Breaking Biology Technology:Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 2Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 3Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 2Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 3New DNA-barcode Patent Virtually Eliminates False Test Results and Sample Mix-up 2
... Vasogen Inc.,(NASDAQ: VSGN ; TSX:VAS), today announced that ... from the Listing Qualifications Department of The NASDAQ,Stock ... of its common,stock had fallen below $1.00 for ... in compliance with Marketplace Rule 4310(c)(4),(the "Rule"). In ...
... 25 Keryx Biopharmaceuticals,Inc. (Nasdaq: KERX ) announced ... Market ("Nasdaq") stating that the Company is not in,compliance ... on the Nasdaq Global Market pursuant to Marketplace Rule ... dated April 22,2008, is a standard communication when the ...
... April 25 ,Renovis, Inc. (Nasdaq: RNVS ), ... Services have joined ISS/Risk Metrics and Glass Lewis,& ... the merger,agreement with Evotec AG (Frankfurt Stock Exchange: ... May 1, 2008. In the proposed merger,each share ...
Cached Biology Technology:Vasogen Receives NASDAQ Notification Related to Minimum Bid Price 2Vasogen Receives NASDAQ Notification Related to Minimum Bid Price 3Keryx Biopharmaceuticals Receives Nasdaq Notification 2Keryx Biopharmaceuticals Receives Nasdaq Notification 3Proxy Governance and Egan-Jones Recommend Renovis Shareholders Vote For Merger With Evotec 2Proxy Governance and Egan-Jones Recommend Renovis Shareholders Vote For Merger With Evotec 3
(Date:7/23/2014)... LAFAYETTE, Ind. Spinach gave Popeye super strength, but ... for a group of scientists: the ability to convert ... University physicists are part of an international group using ... process by which plants convert the sun,s energy into ... we study are part of the most efficient system ...
(Date:7/23/2014)... drought that has the entire country in its grip is ... also be responsible for the proliferation of a heat-loving amoeba ... and hot springs, which the drought has made warmer than ... of an infection caused by this parasite after swimming in ... nose of an individual and travels to the brain. Nose ...
(Date:7/23/2014)... Chrysomya megacephala is commonly found in dead bodies ... time of death, referred to as the post mortem ... C. megacephala from Tamil Nadu is provided for ... characterization through generation of DNA barcoding. This study, significant ... Biodiversity Data Journal . , Chrysomya megacephala ...
Breaking Biology News(10 mins):Spinach could lead to alternative energy more powerful than Popeye 2Diseases of another kind 2Dead body feeding larvae useful in forensic investigations 2
... University and the Denver Crime Lab report in the journal ... to fuse with blood cells in a way that gives ... to enter the bloodstream and seed sites of metastasis around ... marrow transplant patient with cancer, along with DNA fingerprinting of ...
... mutations can reveal a great deal about our immune ... clinical expectations. Australian scientists acknowledge such a gap ... examines people with ,Autosomal Dominant Hyper IgE Syndrome,. ... STAT3 gene. This makes patients slightly more susceptible than ...
... discovered that a human antiviral enzyme causes DNA mutations that ... in the July 14 issue of Nature Genetics , ... is responsible for more than half of breast cancer cases. ... APOBEC3B is part of a family of antiviral proteins that ...
Cached Biology News:CSI-style DNA fingerprinting tracks down cause of cancer spread 2Surprise finding reveals how adaptive our immune systems can be 2Antiviral enzyme contributes to several forms of cancer, University of Minnesota researchers say 2
... leader in electroporation products and specialty electrodes, ... line for experiment optimization and large volume ... breakthrough in Molecular Delivery. The days of ... typically limited the number of samples and ...
... PolarScreen Progesterone Receptor (PR) Competitor Assay ... screening novel progesterone receptor binding compounds ... assay utilizes a fusion of glutathione ... of human progesterone receptor [PR-LBD(GST)] and ...
... Molecular Imaging Systems group announces the ... Digital Imaging Systems, featuring high resolution ... fluorescence, luminescence, radiographic and chromogenic imaging ... CCD and 10x optical zoom lens ...
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selectivity and potential GI liabilities of compounds....
Biology Products: